Medtronic falls 3% as MiniMed insulin pump recalls weigh; shares hit 52-week low
Medtronic shares are sliding as investors refocus on FDA-posted Class II recalls covering certain MiniMed insulin pumps due to a risk of unintended over- or under-delivery when the pump sits too high or low relative to the infusion site. The stock also hit a fresh 52-week low near $80, amplifying downside momentum.
1. What’s moving the stock today
Medtronic (MDT) is down about 3% as the market digests renewed attention on insulin-pump safety actions tied to its MiniMed franchise. The FDA’s recall database shows a Class II recall for the MiniMed 740G System, with the manufacturer warning that insulin over-delivery can occur when the pump is positioned above the infusion site and under-delivery can occur when positioned below it, raising the risk of severe hypoglycemia or hyperglycemia. (accessdata.fda.gov)
2. Why it matters
Even when a recall is managed as a labeling update, usage restrictions, training, and customer communications can disrupt ordering and slow new placements—especially in a competitive diabetes-device market where patient and clinician confidence is central. The FDA posting highlights the mechanism (pressure changes from elevation differences) and the company’s corrective action communications, which investors often treat as a near-term overhang on the diabetes segment’s growth narrative. (accessdata.fda.gov)
3. Price action and setup
The decline is being reinforced by technical pressure after the stock slid to a 52-week low around $79.93 during Wednesday’s session (April 29, 2026). At that point, the shares were also trading well below their prior 52-week high, leaving little near-term chart support for dip buyers. (investing.com)
4. What to watch next
Medtronic’s next major catalyst is its fiscal Q4 earnings report scheduled for Wednesday, June 3, 2026. Any update on diabetes performance, remediation costs, and the trajectory of MiniMed demand will likely determine whether the current drawdown stabilizes or extends. (investorrelations.medtronic.com)